



## MEACOR

### One line pitch:

Meacor is developing a novel catheter-based repair device that replicates the open-heart gold standard for the treatment of mitral valve regurgitation

### Market Analysis:

Approximately 7 million people in the US or 2% of the population suffer from mitral regurgitation, with 250 000 new cases diagnosed every year mainly targeting the elderly. Similar figures are observed in Europe. Of the 4.1 million patients with moderate to severe mitral regurgitation in the U.S., only about 20% are eligible for treatment. However, due to the invasiveness of the current open-heart procedures only 2% actually undergo a surgical intervention. This creates a huge opportunity for the global transcatheter mitral valve repair and replacement market (TMVR) that analysts expect to reach around USD 3.0 billion by 2022 with CAGR of 15.9% during the forecast period of 2016 to 2022.

### Value proposition:

Meacor's device targets the cohort of fragile patients with severe MR that currently are not surgical candidate. Since the etiology of the diseases are many, several therapies are being developed. Meacor has chosen to focus on replicating the open-heart standard of care, ring annuloplasty; being the primary repair on patients with functional MR and secondary for Degenerative MR. Meacor's device presents the following advantages: (i) by reshaping the whole perimeter of the valve, a full annuloplasty can be achieved; (ii) limiting the size of catheter to 15Fr whereas competition are using bigger sizes;

### Business Model:

MEACOR's objective is to perform the required R&D activities to ready the device, initially for chronic animal trials and subsequently for preliminary human trials. Our preferred strategy is the medical technology industry acquisition model, where a large corporation acquires early on a small company that has developed advanced technologies and products in order to enhance their growth. The large corporation will introduce our device in its portfolio and distribute it through its channels.

### IP and Regulatory situation:

MEACOR has filed in 2015 a PCT application entitled: "Device for Soft Tissue Support and Method for Anchoring" which claims a device and method for inserting helicoid anchors using cryogenic catheter in soft tissue. The PCT has been nationalized in the US, Europe, Canada in July 2017, where there is a significant market potential and growth forecast for the Cardiovascular Prosthetic Devices Market. We anticipate to file two more patents, either divisional or continuation in part in the next few months that incorporates the latest designs.



MeaCor

### COMPANY PROFILE

- **Website:**
- **Field:**
- **Contact:**  
AZAR Toufic  
toufic@meacor.com
- **Location:**  
floor 6th Beirut digital district,  
bdd 1294, Bechara el khoury,  
Beirut,  
00000 beirut  
Lebanon
- **Founded in:** //03/2016
- **Employees:** 5
- **Financial information (€):**
  - **Company stage:**  
Proof Of Concept
  - **Capital raised to date:**  
450000
  - **Monthly burn rate:**  
20000
  - **Capital seeking and date:**  
5 million, early 2018
- **Investors:**  
Middle East Venture partners,  
IM capital, ISME Kafalat, 2  
angels